期刊
AMERICAN JOURNAL OF CARDIOLOGY
卷 104, 期 10A, 页码 52E-57E出版社
EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjcard.2009.09.020
关键词
-
资金
- Abbott Laboratories
- AstraZeneca Pharmaceuticals
- Merck Co., Inc.
- Merck/Schering-Plough
- Roche Pharmaceuticals
- Diichi-Sanyo
- Takeda Pharmaceuticals
- Anthera Pharmaceuticals
- AstraZeneca
- Genzyme
- sanofi-aventis
As the significance of treating coronary artery disease (CAD) remains a high priority in reducing morbidity and mortality worldwide, newer treatment strategies continue to evolve. The efficacy of statin therapy in reducing low-density lipoprotein cholesterol and reducing cardiovascular events is well established. Yet, addressing residual macrovascular risk becomes a compelling rationale for proposing that pharmacologic therapy targeted at low concentrations of high-density lipoprotein (HDL) cholesterol is a rationale target for enhanced management of CAD. This article reviews current options for the therapeutic management of HDL cholesterol, including discussion of novel agents aimed at reducing cardiovascular disease risk in patients with low levels of HDL cholesterol. (C) 2009 Elsevier Inc. All rights reserved. (Am J Cardiol 2009; 104[suppl]:52E-57E)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据